Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7527143 | 0.97 | HSD11B1 (0.39) | HSD11B1CYP2C9GRIN2DGRIN3BGRIN1 | |
| SCHEMBL11715655 | 0.84 | GRIN2D (0.38) | HSD11B1CYP2C9GRIN2DGRIN3BGRIN1 | |
| SCHEMBL10927896 | 0.82 | GRIN2D (0.40) | HSD11B1CYP2C9GRIN2DGRIN3BGRIN1 | |
| SCHEMBL906308 | 0.77 | HSD11B1 (0.44) | HSD11B1CYP2C9GRIN2DGRIN3BGRIN1 | |
| Hydrochloric Acid SCHEMBL2386838 | 0.74 | HSD11B1 (0.42) | HSD11B1CYP2C9GRIN2DGRIN3BGRIN1 | |
| SCHEMBL11713892 | 0.73 | — | — | |
| SCHEMBL190682 | 0.72 | HSD11B1 (0.41) | HSD11B1CYP2C9SIGMAR1 | |
| SCHEMBL19594418 | 0.72 | HSD11B1 (0.41) | HSD11B1CYP2C9SIGMAR1 | |
| SCHEMBL7714492 | 0.72 | HSD11B1 (0.41) | HSD11B1CYP2C9SIGMAR1 | |
| SCHEMBL2747594 | 0.72 | HSD11B1 (0.46) | HSD11B1CYP2C9SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| EP-2578212-B1 | COMPOUND INHIBITING ACTIVATION OF THE ENZYME ERK1/2 FOR USE IN THE TREATMENT OF NEUROGENERATIVE ILLNESSES | FARMALIDER SA (ES) | 2016-07-06 | — | — | EP | disclosed |
| US-20150291567-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | GFBIOCHEMICALS LIMITED (MT) | 2015-10-15 | — | — | US | disclosed |
| US-9000047-B2 | Compound inhibiting activation of the enzyme Erk 1/2 to be used in the treatment of neurodegenerative illnesses | FARMALIDER, S.A. (ES) | 2015-04-07 | — | — | US | disclosed |
| US-20140135455-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | SEGETIS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8653223-B2 | Transketalized compositions, synthesis, and applications | SEGETIS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2578212-A1 | COMPOUND INHIBITING ACTIVATION OF THE ENZYME ERK1/2 FOR USE IN THE TREATMENT OF NEUROGENERATIVE ILLNESSES | Farmalider, S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| US-20130065966-A1 | Compound Inhibiting Activation of the Enzyme ERK 1/2 To Be Used In The Treatment Of Neurodegenerative Illnesses | FARMALIDER, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
| US-20110082264-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | SEGETIS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2009146202-A2 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | SEGETIS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| US-6828318-B2 | Amines such as 2-(2-(2-phenyl)adamantyl)ethylamine, used as neurotransmitter antagonists, for prophylaxis of neurodegenerative disorders and as analgesics | VERNALIS RESEARCH LIMITED (GB) | 2004-12-07 | — | — | US | disclosed |
| US-6828318-B2 | Amines such as 2-(2-(2-phenyl)adamantyl)ethylamine, used as neurotransmitter antagonists, for prophylaxis of neurodegenerative disorders and as analgesics | VERNALIS RESEARCH LIMITED (GB) | 2004-12-07 | — | — | US | disclosed |
| EP-1305306-B1 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2004-11-24 | — | — | EP | disclosed |
| US-20030207881-A1 | 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | VERNALIS RESEARCH LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-20030207881-A1 | 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | VERNALIS RESEARCH LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| EP-1305306-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002008219-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
| US-4064135-A | Certain thiazole-5-carboxamide compounds | SYNTEX (U.S.A.) INC. (US) | 1977-12-20 | — | — | US | disclosed |
| US-4064258-A | Thiazole cardiovascular agents | SYNTEX (U.S.A.) INC. (US) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135455-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | TKT, KHK, KYAT3 | HSD11B1 1281/4885CYP2C9 1423/4885GRIN2D 2084/4885 |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | CYFIP2, TPX2, CYFIP1 | HSD11B1 4569/4885CYP2C9 4787/4885GRIN2D 384/4885 |
| US-20130065966-A1 | Compound Inhibiting Activation of the Enzyme ERK 1/2 To Be Used In The Treatment Of Neurodegenerative Illnesses | MAPK1, BACE1, APP | HSD11B1 1974/4885CYP2C9 3407/4885GRIN2D 1604/4885 |
| US-20110082264-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | TKT, KHK, KYAT3 | HSD11B1 1281/4885CYP2C9 1423/4885GRIN2D 2084/4885 |
| US-20030207881-A1 | 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | SLC1A2, SLC18A2, GRM2 | HSD11B1 1563/4885CYP2C9 913/4885GRIN2D 13/4885 |
| US-20150291567-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | TKT, KHK, KYAT3 | HSD11B1 1281/4885CYP2C9 1423/4885GRIN2D 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.